Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1979 Apr;63(4):718–726. doi: 10.1172/JCI109355

Activity of [des-Aspartyl1]-Angiotensin II in Primary Aldosteronism

Robert M Carey 1,2,3, Carlos R Ayers 1,2,3, E Darracott Vaughan Jr 1,2,3, Michael J Peach 1,2,3, Steven M Herf 1,2,3
PMCID: PMC372007  PMID: 438332

Abstract

This study describes the effects of [des-Aspartyl1]-angiotensin II ([des-Asp]-AII) on blood pressure and aldosterone production in patients with primary aldosteronism due to aldosterone-producing adrenal adenoma (APA) and idiopathic adrenal hyperplasia (IHA), and in normotensive control subjects. 10 patients with primary aldosteronism, 7 with APA and 3 with IHA, and 6 normotensive control subjects were placed on a constant 150-meq sodium diet for 4 days. [des-Asp]-AII was infused for 30 min at 6, 12, and 18 pmol/kg per min. Three groups of patients were identified on the basis of aldosterone response to [des-Asp]-AII. Group I, composed of normotensive control subjects, showed incremental increases in plasma aldosterone concentration from 6±1 to 14±3 ng/100 ml (P < 0.01) with [des-Asp]-AII infusion. Group II, composed of patients with primary aldosteronism, showed incremental increases in plasma aldosterone concentration from 33±8 to 65±13 ng/100 ml (P < 0.05) with 12 pmol/kg per min of [des-Asp]-AII. Group III, also composed of patients with primary aldosteronism, showed no increase of plasma aldosterone concentration with [des-Asp]-AII. Groups I and II showed similar percentage increases in plasma aldosterone concentration (P = NS). Group III showed significantly lower aldosterone responses than group I (P < 0.01). Group II included all patients with IHA and two patients with APA. Group III included only patients with APA. The blood pressure responses to [des-Asp]-AII of subjects in group I did not differ significantly from those of groups II or III.

Thus, patients with IHA and a subgroup of patients with APA showed responsiveness to [des-Asp]-AII which was limited to adrenal cortical stimulation of aldosterone biosynthesis. This suggests that adrenal responsiveness to angiotensin is a major control mechanism in some forms of primary aldosteronism. The differential adrenal responsiveness to [des-Asp]-AII in patients with APA indicates either that there are two distinct subpopulations of APA, or that alteration in tumor response to angiotensin occurs during the natural progression of the disease history.

Full text

PDF
719

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AMES R. P., BORKOWSKI A. J., SICINSKI A. M., LARAGH J. H. PROLONGED INFUSIONS OF ANGIOTENSIN II AND NOREPINEPHRINE AND BLOOD PRESSURE, ELECTROLYTE BALANCE, AND ALDOSTERONE AND CORTISOL SECRETION IN NORMAL MAN AND IN CIRRHOSIS WITH ASCITES. J Clin Invest. 1965 Jul;44:1171–1186. doi: 10.1172/JCI105224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baumann K., Müller J. Effect of potassium intake on the final steps of aldosterone biosynthesis in the rat. I. 18-Hydroxylation and 18-hydroxydehydrogenation. Acta Endocrinol (Copenh) 1972 Apr;69(4):701–717. doi: 10.1530/acta.0.0690701. [DOI] [PubMed] [Google Scholar]
  3. Baumann K., Müller J. Effect of potassium intake on the final steps of aldosterone biosynthesis in the rat. II. 11 -hydroxylation. Acta Endocrinol (Copenh) 1972 Apr;69(4):718–730. doi: 10.1530/acta.0.0690718. [DOI] [PubMed] [Google Scholar]
  4. Biglieri E. G., Shambelan M., Slaton P. E., Jr Effect of adrenocorticotropin on desoxycorticosterone, corticosterone and aldosterone excretion. J Clin Endocrinol Metab. 1969 Aug;29(8):1090–1101. doi: 10.1210/jcem-29-8-1090. [DOI] [PubMed] [Google Scholar]
  5. Biglieri E. G., Stockigt J. R., Schambelan M. Adrenal mineralocorticoids causing hypertension. Am J Med. 1972 May;52(5):623–632. doi: 10.1016/0002-9343(72)90053-8. [DOI] [PubMed] [Google Scholar]
  6. Cain J. P., Tuck M. L., Williams G. H., Dluhy R. G., Rosenoff S. H. The regulation of aldosterone secretion in primary aldosteronism. Am J Med. 1972 Nov;53(5):627–637. doi: 10.1016/0002-9343(72)90158-1. [DOI] [PubMed] [Google Scholar]
  7. Carey R. M., Douglas J. G., Schweikert J. R., Liddle G. W. The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone. Arch Intern Med. 1972 Dec;130(6):849–854. [PubMed] [Google Scholar]
  8. Carey R. M., Vaughan E. D., Jr, Ackerly J. A., Peach M. J., Ayers C. R. The immediate pressor effect of saralasin in man. J Clin Endocrinol Metab. 1978 Jan;46(1):36–43. doi: 10.1210/jcem-46-1-36. [DOI] [PubMed] [Google Scholar]
  9. Carey R. M., Vaughan E. D., Jr, Peach M. J., Ayers C. R. Activity of (des-Aspartyl1)-angiotensin II and angiotensin II in man. Differences in blood pressure and adrenocortical response during normal and low sodium intake. J Clin Invest. 1978 Jan;61(1):20–31. doi: 10.1172/JCI108919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ganguly A., Dowdy A. J., Luetscher J. A., Melada G. A. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab. 1973 Feb;36(2):401–404. doi: 10.1210/jcem-36-2-401. [DOI] [PubMed] [Google Scholar]
  11. Ganguly A., Melada G. A., Luetscher J. A., Dowdy A. J. Control of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia. J Clin Endocrinol Metab. 1973 Nov;37(5):765–775. doi: 10.1210/jcem-37-5-765. [DOI] [PubMed] [Google Scholar]
  12. George J. M., Wright L., Bell N. H., Bartter F. C. The syndrome of primary aldosteronism. Am J Med. 1970 Mar;48(3):343–356. doi: 10.1016/0002-9343(70)90065-3. [DOI] [PubMed] [Google Scholar]
  13. Horton R. Stimulation and suppression of aldosterone in plasma of normal man and in primary aldosteronism. J Clin Invest. 1969 Jul;48(7):1230–1236. doi: 10.1172/JCI106087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kem D. C., Weinberger M. H., Gomez-Sanchez C., Kramer N. J., Lerman R., Furuyama S., Nugent C. A. Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism. J Clin Invest. 1973 Sep;52(9):2272–2277. doi: 10.1172/JCI107414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kono T., Oseko F., Shimpo S., Nanno M., Endo J. Biological activity of des-asp1-angiotensin II (angiotensin III) in man. J Clin Endocrinol Metab. 1975 Dec;41(06):1174–1177. doi: 10.1210/jcem-41-6-1174. [DOI] [PubMed] [Google Scholar]
  16. MATTINGLY D. A simple fluorimetric method for the estimation of free 11-hydroxycorticoids in human plasma. J Clin Pathol. 1962 Jul;15:374–379. doi: 10.1136/jcp.15.4.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Newton M. A., Laragh J. H. Effect of corticotropin on aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism. J Clin Endocrinol Metab. 1968 Jul;28(7):1006–1013. doi: 10.1210/jcem-28-7-1006. [DOI] [PubMed] [Google Scholar]
  18. Schambelan M., Brust N. L., Chang B. C., Slater K. L., Biglieri E. G. Circadian rhythm and effect of posture on plasma aldosterone concentration in primary aldosteronism. J Clin Endocrinol Metab. 1976 Jul;43(1):115–131. doi: 10.1210/jcem-43-1-115. [DOI] [PubMed] [Google Scholar]
  19. Slaton P. E., Jr, Schambelan M., Biglieri E. G. Stimulation and suppression of aldosterone secretion in patients with an aldosterone-producing adenoma. J Clin Endocrinol Metab. 1969 Feb;29(2):239–250. doi: 10.1210/jcem-29-2-239. [DOI] [PubMed] [Google Scholar]
  20. Spark R. F., Dale S. L., Kahn P. C., Melby J. C. Activation of aldosterone secretion in primary aldosteronism. J Clin Invest. 1969 Jan;48(1):96–104. doi: 10.1172/JCI105978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Spark R. F., Melby J. C. Aldosteronism in hypertension. The spironolactone response test. Ann Intern Med. 1968 Oct;69(4):685–691. doi: 10.7326/0003-4819-69-4-685. [DOI] [PubMed] [Google Scholar]
  22. Wenting G. J., Man in't Veld A. J., Derkx F. H., Brummelen P. V., Schalekamp M. A. ACTH-dependent aldosterone excess due to adrenocortical adenoma: a variant of primary aldosteronism. J Clin Endocrinol Metab. 1978 Feb;46(2):326–335. doi: 10.1210/jcem-46-2-326. [DOI] [PubMed] [Google Scholar]
  23. Williams G. H., Hollenberg N. K., Moore T. J., Dluhy R. G., Bavli S. Z., Solomon H. S., Mersey J. H. Failure of renin suppression by angiotensin II in hypertension. Circ Res. 1978 Jan;42(1):46–52. doi: 10.1161/01.res.42.1.46. [DOI] [PubMed] [Google Scholar]
  24. Wisgerhof M., Brown R. D. Increased adrenal sensitivity to angiotensin II in low-renin essential hypertension. J Clin Invest. 1978 Jun;61(6):1456–1462. doi: 10.1172/JCI109065. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES